SCHEMBL1927355

SCHEMBL1927355

CC(C)(C)Nc1c(Nc2ccnc(Nc3ccc(C(=O)NC4CCCC4)cc3F)n2)c(=O)c1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 14/20 0.47
PLK3 Q9H4B4 2/20 0.46
PLK2 Q9NYY3 2/20 0.46
SGK1 O00141 1/20 0.46
PLK4 O00444 1/20 0.46
CHEK1 O14757 1/20 0.46
MAPK13 O15264 1/20 0.46
PDPK1 O15530 1/20 0.46
JAK2 O60674 1/20 0.46
ROCK2 O75116 1/20 0.46
CHEK2 O96017 1/20 0.46
FYN P06241 1/20 0.46
CSF1R P07333 1/20 0.46
MET P08581 1/20 0.46
PIM1 P11309 1/20 0.46
FLT1 P17948 1/20 0.46
FGFR3 P22607 1/20 0.46
MARK3 P27448 1/20 0.46
MAPK1 P28482 1/20 0.46
KDR P35968 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1925996 0.87 AURKA (0.47) PLK1PLK3PLK2SGK1PLK4
SCHEMBL1925664 0.86 PLK1 (0.47) PLK1PLK3PLK2SGK1PLK4
SCHEMBL1926129 0.84 PLK1 (0.54) PLK1PLK3PLK2SGK1PLK4
SCHEMBL1926985 0.84 PLK1 (0.48) PLK1PLK3PLK2SGK1PLK4
SCHEMBL1926986 0.84 PLK1 (0.54) PLK1PLK3PLK2SGK1PLK4
SCHEMBL1926287 0.84 PLK1 (0.54) PLK1PLK3PLK2SGK1PLK4
SCHEMBL1928456 0.84 PLK1 (0.52) PLK1PLK3PLK2BRD4PTK2
SCHEMBL1927251 0.83 PLK1 (0.54) PLK1PLK3PLK2SGK1PLK4
SCHEMBL1926374 0.82 LRRK2 (0.49) PLK1PLK3PLK2BRD4PTK2
SCHEMBL1927285 0.81 PLK1 (0.50) PLK1PLK3PLK2RPS6KA3PRKD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7956185-B2 Cyclobut-3-ene-1,2,-dione inhibitors of polo-like kinases ABBOTT LABORATORIES (US) 2011-06-07 US claimed
US-7956185-B2 Cyclobut-3-ene-1,2,-dione inhibitors of polo-like kinases ABBOTT LABORATORIES (US) 2011-06-07 US disclosed
EP-2021316-A1 INHIBITORS OF POLO-LIKE KINASES Abbott Laboratories (US) 2009-02-11 EP disclosed
US-20080015192-A1 INHIBITORS OF POLO-LIKE KINASES ABBVIE INC. 2008-01-17 US disclosed
WO-2007140233-A1 INHIBITORS OF POLO-LIKE KINASES ABBOTT LABORATORIES (US) 2007-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015192-A1 INHIBITORS OF POLO-LIKE KINASES PLK1, PLK2, BUB1B PLK1 1/4885PLK3 19/4885PLK2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.